High Circulating CXCR4+ T cells and Poorer Outcome: A prospective cohort study found that high pretreatment levels of circulating CD8+ CXCR4+ T cells correlated with poorer overall survival (22.0 vs. NR months, HR 0.29, p = 0.02) in NSCLC patients treated with anti-PD-1 ICIs. Here, CXCR4 is linked to non-small cell lung carcinoma.